Drug Approval | March 21, 2023
Caplin receives USFDA approval for Rocuronium Bromide Injection
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
Thiamine Hydrochloride Injection is effective in the treatment of vitamin B1 deficiency (beriberi)
Fluorouracil Injection is indicated for the treatment of patients with adenocarcinoma of colon and rectum and breast
Rocuronium Bromide Injection is a neuromuscular blocking agent
Themis will market this drug with the brand name REMITHEM.
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
